Recent Advancement in the Inhibition of Triple-negative Breast Cancer by N-heterocycles
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Despite the substantial progress that has been made in cancer therapy over the past few decades, there has been a discernible rise in the number of reported instances of carcinoma over the past few decades. Breast cancer especially triple-negative breast cancer (TNBC), being the most common cancer found in females account for extensive research. This type of cancer, which is responsible for more than 15% to 20% of all breast cancers, is particularly interesting for research since it is difficult to treat due to its poor response to treatment and extremely aggressive nature. In clinical practice, triple-negative breast cancer is characterized by a relatively high risk of disease recurrence and distant metastasis, as well as a poor prognosis regarding overall survival. The goal of this review is to provide the recent advancement of the therapeutic potential of N-heterocycles covering in vitro and in vivo activities for the treatment of triple-negative breast cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Anti-cancer agents in medicinal chemistry - 23(2023), 13 vom: 30., Seite 1484-1489 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Choudhury, Badruzzaman [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
in vitro |
|---|
| Anmerkungen: |
Date Completed 29.08.2023 Date Revised 30.08.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1871520623666230330124044 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355103893 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355103893 | ||
| 003 | DE-627 | ||
| 005 | 20231226063637.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1871520623666230330124044 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1183.xml |
| 035 | |a (DE-627)NLM355103893 | ||
| 035 | |a (NLM)37005538 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Choudhury, Badruzzaman |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recent Advancement in the Inhibition of Triple-negative Breast Cancer by N-heterocycles |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.08.2023 | ||
| 500 | |a Date Revised 30.08.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a Despite the substantial progress that has been made in cancer therapy over the past few decades, there has been a discernible rise in the number of reported instances of carcinoma over the past few decades. Breast cancer especially triple-negative breast cancer (TNBC), being the most common cancer found in females account for extensive research. This type of cancer, which is responsible for more than 15% to 20% of all breast cancers, is particularly interesting for research since it is difficult to treat due to its poor response to treatment and extremely aggressive nature. In clinical practice, triple-negative breast cancer is characterized by a relatively high risk of disease recurrence and distant metastasis, as well as a poor prognosis regarding overall survival. The goal of this review is to provide the recent advancement of the therapeutic potential of N-heterocycles covering in vitro and in vivo activities for the treatment of triple-negative breast cancer | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a <i>in vitro</i> | |
| 650 | 4 | |a <i>in vivo</i> | |
| 650 | 4 | |a N-Heterocycles | |
| 650 | 4 | |a Triple-negative breast cancer | |
| 650 | 4 | |a therapeutic | |
| 650 | 4 | |a treatment | |
| 650 | 7 | |a Poly(ADP-ribose) Polymerase Inhibitors |2 NLM | |
| 700 | 1 | |a Chanda, Kaushik |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Anti-cancer agents in medicinal chemistry |d 2006 |g 23(2023), 13 vom: 30., Seite 1484-1489 |w (DE-627)NLM160693403 |x 1875-5992 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:13 |g day:30 |g pages:1484-1489 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1871520623666230330124044 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 13 |b 30 |h 1484-1489 | ||